Compare Nutrien Ltd (NTR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Smith & Nephew plc — how do they compare? Nutrien Ltd trades at $69.92 (market cap $33.31B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: Nutrien Ltd is far larger — about 3× Smith & Nephew plc's market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Smith & Nephew plc for 120 Days on average.
| NTR | SNN | |
|---|---|---|
Market Cap | $33.31B | $11.10B |
Volume | 1,330,729 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $37.17 |
52-Week Low | $53.64 | $26.42 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $45.11B | $14.13B |
Dividend Yield | 3.15% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.97, down 1.73% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation at P/E of 14.14. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations, while analyst consensus remains bullish with $76.14 price target.
NTR presents value opportunity with reasonable valuation and strong agricultural market positioning, though faces headwinds from fertilizer price volatility and competitive pressures. The stock's current discount to analyst targets and oversold technical condition suggest potential upside, but investors should monitor input cost trends and global fertilizer demand dynamics closely.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
